Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2GlobeNewsWire • 02/08/21
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient SettingGlobeNewsWire • 02/04/21
Atea Pharmaceuticals: Early Stage Developer Of Oral Small Molecule SARS-CoV-2 TherapySeeking Alpha • 01/25/21
Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate CommunicationsGlobeNewsWire • 01/19/21
Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/21/20
Atea Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx ConferenceGlobeNewsWire • 11/25/20
U.S. IPO Week Ahead: The IPO Market Takes A Break During The Shortened Holiday WeekSeeking Alpha • 11/22/20
Atea Pharmaceuticals Expands Board of Directors with Appointment of Barbara DuncanGlobeNewsWire • 11/06/20
Atea Pharmaceuticals to offer 11 million shares in IPO, priced at $22 to $24 eachMarket Watch • 10/26/20